MyoKardia to Present at 40th Annual Cowen Health Care Conference

BRISBANE, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Taylor Harris, Chief Financial Officer, will present at the 40th Annual Cowen Health Care Conference on Monday, March 2nd 2020 at 1:30 p.m. EST in Boston.

A webcast of the presentation will be available by visiting the Investors section of MyoKardia’s website at http://investors.myokardia.com. A replay of the webcast will be available on the MyoKardia website for 90 days following the conference.

About MyoKardiaMyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. The company is pioneering a precision medicine approach to its discovery and development efforts by 1) understanding the biomechanical underpinnings of disease, 2) targeting the proteins that modulate a given condition, 3) identifying patient populations with shared disease characteristics and 4) applying learnings from research and clinical studies to inform and guide pipeline growth and advancement. MyoKardia’s initial focus is on small molecule therapeutics aimed at the muscle proteins of the heart that modulate cardiac muscle contraction to address diseases driven by excessive contraction, impaired relaxation, or insufficient contraction. Among its discoveries are three clinical-stage therapeutics: mavacamten (formerly MYK-461) in Phase 3 and Phase 2 clinical trials for hypertrophic cardiomyopathy (HCM); danicamtiv (formerly MYK-491) in Phase 2 for patients with stable heart failure; and MYK-224 in Phase 1 development for HCM.

MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science.

Contacts:

Michelle Corral Corporate Communications & Investor RelationsMyoKardia, Inc.650-351-4690[email protected]Hannah Deresiewicz (investors)Stern Investor Relations, Inc.212-362-1200[email protected]

You May Also Be Interested In

• BOOST Pharma Selected to Showcase Phase III Ready Lead Program BT-101 at the 2026 Cell & Gene Meeting on the Mesa
• Final Phase 2a data reinforce the profile of BIOX-101, selected for a late-breaking oral presentation at the World Stroke Congress
• SELSKABSMEDDELELSE NR. 6/2026 – Årsrapport 2025/26